Amicus Therapeutics Announces Updated Results From Phase 2 Extension Study of Migalastat HCl for Fabry Disease

[at noodls] – Amicus Therapeutics Announces Updated Results From Phase 2 Extension Study of Migalastat HCl for Fabry Disease Kidney Interstitial Capillary GL-3 Results for 60-Week Treatment on Migalastat HCl Presented … more

View todays social media effects on FOLD

View the latest stocks trending across Twitter. Click to view dashboard